Aprea Therapeutics, Inc.
APREAprea Therapeutics is a clinical-stage precision medicine oncology company specializing in the discovery and development of targeted therapies for biomarker-defined cancers.
Table of contents
Earnings
Next report
Aug 11, 2026 (In 1 week)Competitors
Profile
Aprea Therapeutics is a clinical-stage precision medicine oncology company specializing in the discovery and development of targeted therapies for biomarker-defined cancers. The company utilizes the concept of synthetic lethality to develop small molecule inhibitors that selectively destroy cancer cells with specific genetic mutations while sparing healthy tissue. Their primary focus is on addressing DNA damage response (DDR) pathways to treat high-unmet-need malignancies.
A clinical-stage developer focused on best-in-class potential for WEE1 and ATR inhibitors through improved selectivity and therapeutic index.
Questions, answered.
- What is Aprea Therapeutics, Inc.'s market cap?
- Aprea Therapeutics, Inc. (APRE) has a market capitalization of $7.7M and trades on NASDAQ.
- Who are Aprea Therapeutics, Inc.'s competitors?
- Aprea Therapeutics, Inc.'s key competitors include Acrivon Therapeutics, Zentalis Pharmaceuticals, Prelude Therapeutics Incorporated, and others. These companies compete in similar markets and product categories.
- Who does Aprea Therapeutics, Inc. partner with?
- Aprea Therapeutics, Inc.'s notable partners include MD Anderson Cancer Center, AstraZeneca, Zentalis Pharmaceuticals.
- What subsidiaries does Aprea Therapeutics, Inc. have?
- Aprea Therapeutics, Inc.'s subsidiaries include Aprea Therapeutics AB, Atrin Pharmaceuticals Inc..
- Where is Aprea Therapeutics, Inc. headquartered?
- Aprea Therapeutics, Inc. is headquartered in United States of America and employs approximately 7 people. It has been publicly traded since 2019.